BioNTech SE, a prominent German biotechnology company headquartered in Mainz, recently reported a significant change in beneficial ownership. This development occurred on September 11, 2026, following a transaction by the company’s chief executive officer (CEO), who is also a substantial shareholder. The CEO executed a sale of a portion of their ordinary shares under a rule-based trading plan.
As of September 3, 2026, BioNTech SE’s close price on the Vienna Stock Exchange was recorded at 89.6 EUR. The company’s stock has experienced fluctuations over the past year, reaching a 52-week high of 105.7 EUR on January 21, 2026, and a 52-week low of 68.3 EUR on March 9, 2026. BioNTech SE’s market capitalization stands at 20,463,171,584 EUR, reflecting its substantial presence in the biotechnology sector.
The CEO’s sale resulted in a decrease in their direct ownership of BioNTech SE shares. However, the CEO’s overall holding remains significant through a related entity, with the majority of shares held indirectly. The filing disclosed that a trust arrangement governs a portion of these shares. Under this arrangement, the reporting person retains the ability to exercise voting rights, while the trust maintains dispositive control over the shares.
No other material corporate events were disclosed in the filing, indicating that the change in beneficial ownership was the primary focus of the recent announcement. BioNTech SE continues to specialize in developing biotechnological solutions, particularly treatments for cancer patients’ tumors, serving a global customer base. Further information about the company’s work and initiatives can be accessed on their website at www.biontech.de . The company is listed on the Xetra stock exchange, further emphasizing its prominence in the biotechnology industry.
